330 Coronary interventions: stents lar in group III (9,12±2,65 mg/l la 11,91±1,81 mg/l), reflected by encreasing the hs-CRP level (p<0.05). Conclusions: Patients with a stent length ≥30 mm versus those with a shorter stent (≤15 mm) already had a higher level of both pro-oxidant markers (ischemia modified albumin, malondialdehyde) and an inflammatory marker (hs-CRP) before percutaneous angioplasty, showing a more advanced atherosclerotic process. The traumatic impact of coronary angioplasty is manifested by subsequent post-PCI elevation of these markers also expressed in the stent-length group ≥30 mm.
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Evaluation of transradial versus transfemoral procedures in all-comers patients treated with the dual-therapy stent
Background and introduction:
Transradial catheterization has become the primary choice of percutaneous coronary intervention (PCI) strategy for most interventional cardiologists due to lower complications rates when compared to transfemoral catheterization. The COMBO Collaboration is a contemporary cohort of 3614 all-comers patients who are treated with the dual-therapy stent (DTS), with either a radial or femoral access site. We evaluate differences in patient characteristics and clinical outcomes after PCI according to access site. Purpose: To determine which patients still receive transfemoral PCI and if transfemoral procedure influences clinical outcomes at 1 year follow-up. Methods: The the COMBO Collaboration consists of all patients from the prospective, multicenter, all-comers REMEDEE and MASCOT registries, that evaluate outcomes after DTS stent placement. For all patients baseline and procedural characteristics were collected in an electronic database. Independent clinical event committees adjudicated all adverse events. Patients with brachial or other access site were excluded from this analysis Target lesion failure (TLF) consisting of cardiac death, target vessel myocardial infarction (TV-MI) and clinically indicated target lesion revascularization (TLR). Results: Radial access was used in 2461 patients (69.4%), femoral access in 1083 patients (30.6%). Radial procedures were the standard in Europe (71.0%) and Asia (71.8%) but in the Middle East and South America femoral procedures were more frequent (54.7%). A higher percentage of females was observed in femoral procedures (26.5% versus 22.8%, p=0.02) but age and presence of diabetes mellitus did not significantly differ between groups. Previous PCI was higher in patients with femoral procedures (29.8 versus 25.4%, p<0.01) as was peripheral vascular disease (5.0% versus 8.3%, p<0.01) and chronic kidney disease was significantly higher in (9.3% versus 5.2%, p<0.001). A numerical but not statistical significant trend in higher TLF at one year was seen in patients with transfemoral procedure (3.5% versus 4.6%, p=0.09), with more early events.
1-year TLF according to access site.
Conclusion(s):
In a contemporary all-comers cohort of over 3600 patients treated with DTS transradial procedures were more frequent than transfemoral procedures. Patients with transfemoral access site had more comorbidities. Clinical outcomes did not significantly differ according to access site, although numerically higher early adverse events are observed after transfemoral procedures. Funding Acknowledgements: The AMC received an unrestricted research grant from OrbusNeich Medical BV. OrbusNeich Medical BV. was the sponsor of the MASCOT trial.
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Impact of triglyceride deposit cardiomyovasculopathy, a novel type atherosclerosis with triglyceride deposition in coronary arteries, on neointimal proliferation after coronary stent-implantation Y. Nakano, M. Suzuki, T. Niwa, A. Suzuki, M. Shimoda, A. Satake, H. Ando, H. Takashima, K. Waseda, T. Amano. Aichi Medical University, Nagakute, Japan Background: Triglyceride deposit cardiomyovasculopathy (TGCV) is characterized by the massive accumulation of triglyceride in myocardia and coronary arteries, leading to cardiomyocyte steatosis and a novel atherosclerosis with triglyceride deposition in smooth muscle cells. Neointimal proliferation after drug-eluting stents implantation in patients with TGCV are considered to be enhanced, however, there are no real-world data. Aim: The aim of this study was to evaluate in-stent late loss and its associate data using quantitative coronary angiography (QCA) analysis in patients with TGCV. Methods: Among 457 consecutive patients who underwent both coronary angiography and iodine-123-β-methyliodophenyl-pentadecanoic acid (BMIPP) scintigraphy between 2010 and 2017, 18 patients were met the diagnostic criteria for TGCV (as shown in Figure) . Out of 18 patients, 10 TGCV patients (TGCV group, n=10) who were implanted second or third generation drug-eluting stent for the treatment of coronary lesions, and age-and sex-matched 20 non-TGCV controls with diabetes (non-TGCV group, n=20) were compared. Baseline, pre-and post-QCA analysis were performed in 22 stents of TGCV group and 22 stents of non-TGCV group. Results: There were no significant differences in baseline characteristics between the 2 groups, except for stent length and hemodialysis. Although minimum lumen diameter (MLD) at pre and post PCI were similar between the 2groups, MLD at follow-up was significantly smaller in TGCV compared with non-TGCV. Similarly, greater diameter stenosis and late loss were observed in TGCV comDownloaded from https://academic.oup.com/eurheartj/article-abstract/39/suppl_1/ehy565.P1660/5081490 by guest on 06 December 2018
